Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma
- 24 June 2020
- journal article
- research article
- Published by Impact Journals, LLC in Aging
- Vol. 12 (12), 11466-11484
- https://doi.org/10.18632/aging.103231
Abstract
Hepatocellular carcinoma (HCC) is a heterogeneous malignancy with gender-related differences in onset and course. Androgen receptor (AR), a male hormone receptor, is critical in the initiation and progression of HCC. The role of AR in HCC has been mechanistically characterized and anti-AR therapies have been developed, showing limited efficacy. Immunotherapy targeting immune checkpoint proteins may substantially improve the clinical management of HCC. The mechanism by which AR influences HCC immune state remains unclear. In this study, we demonstrated that AR negatively regulated PD-L1, by acting as a transcriptional repressor of PD-L1. Notably, AR over-expression in HCC cells enhanced CD8(+)T function in vitro. We then verified the AR/PD-L1 correlation in patients. In animal experiment we found that lower AR expressed tumor achieved better response to PD-L1 inhibitor. Thus, AR suppressed PD-L1 expression, possibly contributing to gender disparity in HCC. Better understanding of the roles of AR during HCC initiation and progression will provide a novel angle to develop potential HCC immunotherapies.Keywords
This publication has 46 references indexed in Scilit:
- Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitisEndocrine-Related Cancer, 2014
- Androgen receptor signaling in prostate cancerCancer and Metastasis Reviews, 2014
- Acetylcholine Acts on Androgen Receptor to Promote the Migration and Invasion but Inhibit the Apoptosis of Human HepatocarcinomaPLOS ONE, 2013
- PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25ACell Cycle, 2012
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyThe New England Journal of Medicine, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikisHepatology, 2012
- Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connectionHepatology, 2010
- Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifenHepatology, 2004
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002